A partnership track is the published sequence of pay structures that moves an employed pediatrician from salary to ownership. Each phase shifts more financial risk onto the physician and asks for something new: fit and clinical footing first, a disciplined response to a production incentive next, then the ability to cover their full compensation cost on a percent of revenue, and finally a share of the practice's profits.
The short answer. An employed pediatrician becomes a partner in four phases: a flat salary with a discretionary bonus in year one, salary plus a production incentive from year two onward through roughly year five, a reduced base with a straight percent of revenue as an associate partner, and full partnership with a share of practice profits. The production incentive starts once a trailing twelve months clears the gate, meaning the physician's full compensation cost plus allocated overhead. The practice watches behavior at every step. Ownership comes only after the physician has spent real time covering their full compensation cost, and stepping back from the third phase to the second carries no penalty.
The request usually arrives before the plan does. A productive employed physician wants more pay and more time off on the same schedule, plus a say in how the practice runs. The owners value the production and aren't sure about the person. Nothing on paper tells either side what partnership requires, so every request turns into a one-off negotiation that still has to be fair to every other employed physician.
PMI starts with motivation. Money can be fixed. PTO can be fixed too, on one condition the physician has to accept: time out of the office generates no revenue, so earnings fall as time off rises. What no formula fixes is entrepreneurial spirit, and in PMI's experience that can't be taught.
PMI runs three tests before any admission decision. The first is the partner conversation: the owners picture the candidate seated with them as they weigh a future partner, and ask whether that physician would add judgment to the discussion or only argue for their own terms. A production report can't answer that.
The second is the staff read. The owners consider how the whole team would react to hearing that this physician is now an owner. Whether the reaction lands positive, negative or neutral is data about leadership, and it belongs in the decision.
The third is a project. The owners assign a real, time-bound piece of work the practice needs, such as a new workflow, a recall process or a system rollout, and watch the execution. Whether the idea was the candidate's matters less than whether the candidate finishes it. That's the attribute PMI prizes most in a future partner: the instinct to read a situation, ask how it affects the business and go fix the problem.
PMI's roadmap has four phases. The date ranges can move to fit the practice.
Phase 3 carries the most weight. A physician without the appetite to believe in their own ability to generate revenue is unlikely to be a productive partner, so the owners need to see a stretch of time when the physician is on the hook and handles that pressure well. Physicians on a percent of revenue also become highly motivated to help with patient recall and efficiency.
The common shortcut is Phase 2 straight to Phase 4. A practice that takes it never learns whether the physician covers their cost under owner-level risk, and finds out after the vote.
Every production incentive needs a citizenship component. PMI's baseline gates:
A complaint under an incentive model starts with a conversation about severity. A scheduling complaint, a communication complaint and a clinical-conduct complaint carry different weight, and the talk comes before any change to pay. No decision tree covers every case.
The caution grows with the incentive. Extreme incentives can turn colleagues into competitors for the same patients and the same appointment slots, and PMI has seen it happen. A straight percent of revenue is that kind of structure. It belongs late in the track, never in a new hire's offer letter, and scheduling behavior deserves a close watch wherever the incentive is high.
Two rules hold regardless. Call rotation doesn't change with a new pay architecture or title, unless the partnership agreement explicitly allows it. And a physician who struggles on a percent of revenue in Phase 3 can return to salary plus incentive in Phase 2 with no penalty, so the agreement should spell out that return path.
Every incentive starts with an affordability line. Breakeven revenue equals total provider cost divided by one minus the overhead rate, and the threshold adds a cushion of 5 to 10 percent of revenue above breakeven before any incentive dollar is paid. A physician costing $184,000 fully loaded in a practice running 60% overhead breaks even at $460,000 of collections. Incentive dollars above the threshold are funded by construction. That breakeven line is also the gate into Phase 2, and the cost in the formula is the full compensation cost, benefits included, never base salary alone. A physician below breakeven is being subsidized, and the practice cannot subsidize an individual physician's earnings.
A percent of revenue follows the same logic, since overhead and physician compensation together can't exceed collections. One practice PMI works with landed at 25% of revenue and later moved to 30% once the overhead rate proved lower than expected. Both sit inside the 25% to 35% band PMI treats as healthy for compensation divided by collections, with 20% to 40% still defensible.
Vaccine drugs stay out for a compliance reason. Medicaid, a federal program, makes up 30% to 60% of most pediatric panels, and federal self-referral and anti-kickback rules permit productivity pay on services a physician personally performs. PMI's drafting standard therefore keeps vaccine drugs, clinical lab and any designated health services out of every bonus base. Administering the vaccine is personally performed work, so it counts.
The same allocation decides what a departing partner is paid. A partner's accounts receivable payout at departure includes vaccine drug and lab revenue only if the pay formula charged that partner the cost of those items, and where the costs were never allocated, that revenue stays out of the payout. A flat percentage haircut is not a substitute, because vaccine volume varies by physician and a panel with fewer newborns carries fewer shots. PMI sees this as the most common point of contention at a partner's exit.
In Phases 2 through 4 the practice runs that math for every physician and APP, every month, on a trailing twelve months: collections net of vaccine drugs and lab, less overhead at the published rate, less the full compensation cost. A single month or quarter misleads, because pediatric volume swings with flu and physical seasons and collections arrive weeks to months after the visit. The margin that remains is the gate into Phase 2, the funding source for every incentive dollar, and in Phases 3 and 4 the proof that the physician covers full cost. Year one is the exception that has to be admitted up front. The practice carries twelve months of expense for a new physician and normally collects about ten months of revenue, since credentialing lag and the ramp to a full panel eat the rest, so the first year reads as a ramp against budget rather than a margin verdict.
Phase 4 adds income a percent of revenue never reaches. In one worked example, 21.7% of an owner's income came from employed-provider margins.
The hot rail sits between Phase 3 and Phase 4. An associate partner earning well on a percent of revenue will eventually ask why a six-figure buy-in is worth a possible pay cut. The buy-in has to make sense against what ownership adds above an associate partner's pay, measured over the long term rather than in the first year. It also has to be financeable. In PMI's affordability example, $50,000 a year available for debt service supports a $194,483 price at 9% over five years.
Time at the practice generally governs placement on the track, but prior experience counts. Two physicians might join in the same month, one fresh from residency and one with 10 years elsewhere. Two years in, the experienced one is more likely to handle a production incentive, even a high one, and can reasonably move faster. Pediatricians generally plateau clinically three or four years out of residency, and after that, PMI's view is that personality shapes the quality of most visits more than added years do.
Sometimes the physician is ready and the practice isn't. Build-out debt, personal guarantees on the lease and an unfinished buyout of a former partner are legitimate reasons to delay full partnership, because a new partner has to be legally attached to every liability of the practice. That's a fair basis for telling a candidate the owners need more time. A deferral should never arrive as silence. It comes with a written interim plan and a date to revisit. For a Phase 2 physician the interim step is the associate-partner percentage. For a Phase 3 physician it is continuing Phase 3 with a tenure step-up in the percentage and a written revisit date. How the candidate takes a reasoned deferral reveals more than any interview.
Time off under a percent of revenue is self-regulating, as long as the practice sets a minimum number of providers per day and expects a physician who wants a day off to trade call. A physician unconcerned about coverage is putting personal interest ahead of the practice and isn't thinking like an owner. And any outside patient care needs its own malpractice coverage, confirmed with the practice's carrier before the work starts.
Between Phase 3 and Phase 4 sits one more exchange, and the owners should welcome it. An associate partner who asks for the practice's financial statements, tax returns, payer contracts, malpractice history, leases and the partnership agreement itself is behaving like an owner already. PMI's guidance to owners is that a well-run practice has nothing to fear from the request: healthy numbers speak for themselves, full disclosure is the practice's best protection against disputes after closing, and a buyer who cannot get information either walks away or drags the process out. The reasonable version of that request follows the PMI Due Diligence Checklist, scoped for a physician buying into an existing independent practice rather than a third-party acquisition, and a practice that ran Phases 2 and 3 as designed already holds much of it: the trailing-twelve-month margin reports, the incentive history, the worked buy-in example and the liability disclosure schedule. Patient-identifiable data, staff members' personal files and other partners' personal finances stay out. De-identified reports and summaries answer those questions instead.
The track should go to every employed physician, including those who haven't asked, so each can see where they stand. PMI's advice is to present it as a logical path with the expected behavior named at each phase, never as a sales pitch. No phase guarantees the next. When a physician presses for partnership, the answer is short and written down: readiness means covering their full compensation cost, sustained, with the citizenship gates intact.
One more thing belongs on the map, and it changes how the whole track reads. Phase 4 is not the finish line. The first three phases are the warm-up: they prove that a physician can produce, carry risk and act like an owner before holding an owner's rights. Ownership is where the real journey begins, with the hiring decisions, the debt, the payer fights and the responsibility for every other paycheck in the building. A track that ends at admission has described the tryout and left out the season.
On the roadmap PMI uses, year one is salary with a discretionary bonus, a production incentive runs from year two onward, once a trailing twelve months clears the gate, through roughly year five, and a percent of revenue as an associate partner follows after that. Full partnership comes once the physician has proven, over real time, an ability to cover their full compensation cost, benefits included, plus allocated overhead. Prior experience can speed the early phases, and outstanding practice debt can delay the last one.
It should include vaccine administration and exclude vaccine drugs and labs. Giving the vaccine is a service the physician personally performs, and federal rules permit productivity pay on those services. PMI's compliance drafting keeps vaccine drugs, clinical lab and any designated health services out of every bonus base. Once the physician becomes a full partner, the drug margin is one of the profit sources partners share.
Yes. PMI's track allows a return from Phase 3 to Phase 2, salary plus a production incentive based on a percent of revenue, RVUs, charges or visits, with no harm done. Some physicians find a reduced base with a straight percent of revenue doesn't suit them. The practice still needs to see a period in which a future partner was on the hook and handled the pressure well.
PMI helps pediatric practice owners build partnership tracks and the buy-in math behind them. Start with the PMI partnership resource hub, or schedule a discovery call to map the track against a practice's own overhead rate.
This article is general guidance for pediatric practice owners and is not legal, tax or valuation advice. Engage counsel and a CPA before changing any employment or partnership agreement.